EMA recommends Covid-19 vaccination for children as young as 5

The European Medicines Agency's (EMA) special committee, the CHMP, has recommended the Pfizer-Biontech vaccine for children between the ages of 5 and 11.

by ritzau, translated by daniel pedersen

Published: 25.11.21 at 15:01

On Thursday, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommends the approval of Covid-19 developed by Pfizer and Biontech for use in children aged 5 to 11 years.

The extended indication of the vaccine, which is known as Comirnaty, will still need to be officially approved by the European Commission before children as young as 5 can receive their first shots. This approval, however, is typically considered a mere formality.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.